dipyridamole has been researched along with Chagas Cardiomyopathy in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Chagas Cardiomyopathy: A disease of the CARDIAC MUSCLE developed subsequent to the initial protozoan infection by TRYPANOSOMA CRUZI. After infection, less than 10% develop acute illness such as MYOCARDITIS (mostly in children). The disease then enters a latent phase without clinical symptoms until about 20 years later. Myocardial symptoms of advanced CHAGAS DISEASE include conduction defects (HEART BLOCK) and CARDIOMEGALY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dipyridamole (DPY) is an alternative to counteract the pathophysiological phenomena involved in Chagas cardiomyopathy." | 3.85 | Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis. ( Alvarez, C; Bonfante-Cabarcas, R; Bonfante-Rodríguez, R; Caicedo, P; Giraldo, E; Rodríguez-Bonfante, C; Santeliz, S; Yustiz, MD, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santeliz, S | 1 |
| Caicedo, P | 1 |
| Giraldo, E | 1 |
| Alvarez, C | 1 |
| Yustiz, MD | 1 |
| Rodríguez-Bonfante, C | 1 |
| Bonfante-Rodríguez, R | 1 |
| Bonfante-Cabarcas, R | 1 |
| Tanaka, DM | 1 |
| de Oliveira, LFL | 1 |
| Marin-Neto, JA | 1 |
| Romano, MMD | 1 |
| de Carvalho, EEV | 1 |
| de Barros Filho, ACL | 1 |
| Ribeiro, FFF | 1 |
| Cabeza, JM | 1 |
| Lopes, CD | 1 |
| Fabricio, CG | 1 |
| Kesper, N | 1 |
| Moreira, HT | 1 |
| Wichert-Ana, L | 1 |
| Schmidt, A | 1 |
| Higuchi, ML | 1 |
| Cunha-Neto, E | 1 |
| Simões, MV | 1 |
| Petretta, M | 1 |
| Cuocolo, A | 1 |
| Kuschnir, E | 1 |
| Sgammini, H | 1 |
| Castro, R | 1 |
| Evequoz, C | 1 |
| Ledesma, R | 1 |
4 other studies available for dipyridamole and Chagas Cardiomyopathy
| Article | Year |
|---|---|
Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis.
Topics: Acute Disease; Animals; Chagas Cardiomyopathy; Dipyridamole; Disease Models, Animal; Drug Synergism; | 2017 |
Prolonged dipyridamole administration reduces myocardial perfusion defects in experimental chronic Chagas cardiomyopathy.
Topics: Animals; Chagas Cardiomyopathy; Cricetinae; Dipyridamole; Disease Models, Animal; Echocardiography; | 2019 |
The long way to defeating Chagas cardiomyopathy.
Topics: Cardiomyopathies; Chagas Cardiomyopathy; Chagas Disease; Dipyridamole; Humans | 2019 |
[Chronic Chagas' cardiomyopathy: effects of dipyradamole on ventricular dynamics].
Topics: Adult; Aged; Chagas Cardiomyopathy; Dipyridamole; Female; Heart; Heart Ventricles; Humans; Male; Mid | 1983 |